Evaluation of Different Protocols for Gene Transfer into Non-obese Diabetes/severe Combined Immunodeficiency Disease Mouse Repopulating Cells

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2006 Oct 21

PMID 17053889

Authors

Peter Ebeling

P Bach

U Sorg

A Schneider

T Trarbach

D Dilloo

H Hanenberg

S Niesert

S Seeber

T Moritz

M Flasshove

Affiliations

Soon will be listed here.

Abstract

Purpose: Although gene transfer with retroviral vectors has shown distinct clinical success in defined settings, efficient genetic manipulation of hematopoietic progenitor cells remains a challenge. To address this issue we have evaluated different transduction protocols and retroviral constructs in the non-obese diabetes (NOD)/severe combined immunodeficiency disease (SCID) xenograft model.

Methods: An extended transduction protocol requiring 144 h of in vitro manipulation was compared to a more conventional protocol requiring 96 h only.

Result: While pretransplantation analysis of cells transduced with a retroviral vector, expressing the enhanced green fluorescent protein (EGFP) marker gene, demonstrated significantly higher overall transduction rates for the extended protocol (33.6 +/- 2.3 vs. 22.1 +/- 3.8%), EGFP expression in CD34+ cells before transplantation (4.0 +/- 0.9 vs. 11.6 +/- 2.5%), engraftment of human cells in NOD/SCID bone marrow 4 weeks after transplantation (4.5 +/- 1.7 vs. 36.5 +/- 9.4%) and EGFP expression in these cells (0 +/- 0 vs. 11.3 +/- 2.8%) were significantly impaired. When the 96 h protocol was used in combination with the spleen focus forming virus (SFFV)/murine embryonic stem cell (MESV) hybrid vector SFbeta11-EGFP, high transduction rates for CD45+ (41.0 +/- 5.3%) and CD34+ (38.5 +/- 3.7%) cells prior to transplantation, as well as efficient human cell engraftment in NOD/SCID mice 4 weeks after transplantation (32.4 +/- 3.5%), was detected. Transgene expression was observed in B-lymphoid (15.9 +/- 2.0%), myeloid (36.5 +/- 3.5%) and CD34+ cells (10.1 +/- 1.5%).

Conclusion: Our data show that CD34+ cells maintained in cytokines for multiple days may differentiate and loose their capacity to contribute to the haematological reconstitution of NOD/SCID mice. In addition, the SFFV/MESV hybrid vector SFbeta11-EGFP allows efficient transduction of and gene expression in haematopoietic progenitor cells.

References

Dorrell C, Gan O, Pereira D, Hawley R, Dick J . Expansion of human cord blood CD34(+)CD38(-) cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: dissociation of SRC phenotype and function. Blood. 1999; 95(1):102-10. View

Hanenberg H, Xiao X, Dilloo D, Hashino K, Kato I, Williams D . Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med. 1996; 2(8):876-82. DOI: 10.1038/nm0896-876. View

Ballen K, Becker P, Greiner D, Valinski H, Shearin D, Berrios V . Effect of ex vivo cytokine treatment on human cord blood engraftment in NOD-scid mice. Br J Haematol. 2000; 108(3):629-40. DOI: 10.1046/j.1365-2141.2000.01865.x. View

Moritz T, Dutt P, Xiao X, Carstanjen D, Vik T, Hanenberg H . Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood. 1996; 88(3):855-62. View

Yokota T, Oritani K, Mitsui H, Aoyama K, Ishikawa J, Sugahara H . Growth-supporting activities of fibronectin on hematopoietic stem/progenitor cells in vitro and in vivo: structural requirement for fibronectin activities of CS1 and cell-binding domains. Blood. 1998; 91(9):3263-72. View

Hanenberg H, Batish S, Pollok K, Vieten L, Verlander P, Leurs C . Phenotypic correction of primary Fanconi anemia T cells with retroviral vectors as a diagnostic tool. Exp Hematol. 2002; 30(5):410-20. DOI: 10.1016/s0301-472x(02)00782-8. View

Larochelle A, Vormoor J, Hanenberg H, Wang J, Bhatia M, Lapidot T . Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: implications for gene therapy. Nat Med. 1996; 2(12):1329-37. DOI: 10.1038/nm1296-1329. View

Gatlin J, Melkus M, Padgett A, Kelly P, Garcia J . Engraftment of NOD/SCID mice with human CD34(+) cells transduced by concentrated oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein. J Virol. 2001; 75(20):9995-9. PMC: 114573. DOI: 10.1128/JVI.75.20.9995-9999.2001. View

Horn P, Thomasson B, Wood B, Andrews R, Morris J, Kiem H . Distinct hematopoietic stem/progenitor cell populations are responsible for repopulating NOD/SCID mice compared with nonhuman primates. Blood. 2003; 102(13):4329-35. DOI: 10.1182/blood-2003-01-0082. View

10.

Dao M, Hashino K, Kato I, Nolta J . Adhesion to fibronectin maintains regenerative capacity during ex vivo culture and transduction of human hematopoietic stem and progenitor cells. Blood. 1998; 92(12):4612-21. View

11.

Denning-Kendall P, Singha S, Bradley B, Hows J . Cytokine expansion culture of cord blood CD34+ cells induces marked and sustained changes in adhesion receptor and CXCR4 expressions. Stem Cells. 2003; 21(1):61-70. DOI: 10.1634/stemcells.21-1-61. View

12.

Hennemann B, Conneally E, Pawliuk R, Leboulch P, Rose-John S, Reid D . Optimization of retroviral-mediated gene transfer to human NOD/SCID mouse repopulating cord blood cells through a systematic analysis of protocol variables. Exp Hematol. 1999; 27(5):817-25. DOI: 10.1016/s0301-472x(99)00021-1. View

13.

Piacibello W, Bruno S, Sanavio F, Droetto S, Gunetti M, Ailles L . Lentiviral gene transfer and ex vivo expansion of human primitive stem cells capable of primary, secondary, and tertiary multilineage repopulation in NOD/SCID mice. Nonobese diabetic/severe combined immunodeficient. Blood. 2002; 100(13):4391-400. DOI: 10.1182/blood.V100.13.4391. View

14.

Ng Y, Bloem A, van Kessel B, Lokhorst H, Logtenberg T, Staal F . Selective in vitro expansion and efficient retroviral transduction of human CD34+ CD38- haematopoietic stem cells. Br J Haematol. 2002; 117(1):226-37. DOI: 10.1046/j.1365-2141.2002.03370.x. View

15.

Guenechea G, Segovia J, Albella B, Lamana M, Ramirez M, Regidor C . Delayed engraftment of nonobese diabetic/severe combined immunodeficient mice transplanted with ex vivo-expanded human CD34(+) cord blood cells. Blood. 1999; 93(3):1097-105. View

16.

Gothot A, Giet O, Huygen S, Beguin Y . Binding and migration across fibronectin and VCAM-1 of cycling hematopoietic progenitor cells. Leuk Lymphoma. 2003; 44(8):1379-83. DOI: 10.1080/1042819031000083406. View

17.

Hanenberg H, Hashino K, Konishi H, Hock R, Kato I, Williams D . Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. Hum Gene Ther. 1998; 8(18):2193-206. DOI: 10.1089/hum.1997.8.18-2193. View

18.

Carstanjen D, Dutt P, Moritz T . Heparin inhibits retrovirus binding to fibronectin as well as retrovirus gene transfer on fibronectin fragments. J Virol. 2001; 75(13):6218-22. PMC: 114340. DOI: 10.1128/JVI.75.13.6218-6222.2001. View

19.

Liu B, Buckley S, Lewis I, Goldman A, Wagner J, van der Loo J . Homing defect of cultured human hematopoietic cells in the NOD/SCID mouse is mediated by Fas/CD95. Exp Hematol. 2003; 31(9):824-32. DOI: 10.1016/s0301-472x(03)00161-9. View

20.

Ahmed F, Ings S, Pizzey A, Blundell M, Thrasher A, Ye H . Impaired bone marrow homing of cytokine-activated CD34+ cells in the NOD/SCID model. Blood. 2003; 103(6):2079-87. DOI: 10.1182/blood-2003-06-1770. View